Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01068782 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class

Stopped Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.

Conditions

Interventions

Sponsor

Exelixis